If a patient becomes pregnant during the study, she will discontinue study medication immediately and be followed appropriately. Subjects with uncontrolled hypertension, defined as a systolic blood pressure greater than 180mm Hg or diastolic blood pressure greater than 100mm Hg. Subjects with significant disease that may affect the patient's management in this study, such as pulmonary disease, heart disease, cancer or other diseases that may limit life expectancy. Subjects with any clinically significant laboratory abnormality as determined by the primary investigator. Subjects taking any serotonin-affecting medications within one month of the start of the study.
Inhibitors Subjects taking anticonvulsants or neuroleptics.
Subjects with schizophrenia, psychotic symptoms, history of psychosis, bipolar disorders, organic brain syndrome, dementia, mental retardation, or any other disorder that might interfere with the patient's ability to consent or to follow study requirements. Subjects diagnosed with hyperthyroidism prior to or during baseline medical examination. 6.4 Subject Qualification Subjects who meet the screening visit inclusion and exclusion criteria will be administered the Informed Consent. Following successful Informed Consent completion, the subject will be scheduled for the baseline medical assessment and administration of the Fibromyalgia Impact Questionnaire, Zung Depression scale, and Algometry studies.